Related Experiment Video
Updated: Dec 8, 2025
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
5.1K
Summary
Pioglitazone is the sole insulin sensitizer, offering vascular benefits beyond blood sugar control. This review covers its cardiovascular trials, safety, and usage recommendations.
Area of Science:
- Pharmacology
- Cardiology
- Metabolic Disorders
Background:
- Pioglitazone is a key drug for reducing insulin resistance.
- It is currently the only available insulin sensitizer.
- Beyond its hypoglycemic effects, pioglitazone exhibits beneficial metabolic actions on the vascular wall.
Purpose of the Study:
- To provide an overview of cardiovascular clinical trials involving pioglitazone.
- To assess the safety profile of pioglitazone.
- To offer practical recommendations for pioglitazone administration.
Main Methods:
- Review of cardiovascular clinical trials.
- Analysis of safety data.
- Synthesis of evidence for clinical recommendations.
Main Results:
- Pioglitazone demonstrates positive effects on the vascular wall.
- Cardiovascular trial data and safety profiles were evaluated.
- Evidence supports practical administration guidelines.
Conclusions:
- Pioglitazone offers significant vascular benefits.
- Understanding its safety profile is crucial for effective use.
- Clinical recommendations facilitate optimal patient management.
More Related Videos
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
428
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
428
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
502
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
502
01:06Oral Hypoglycemic Agents: Glinides
468
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
468
01:24Glucagon-like Receptor Agonists
673
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
673
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
434
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
434
01:17Oral Hypoglycemic Agents: Sulfonylureas
606
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
606